CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer

EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation

(2018) Daniel Zingg et al.   CANCER CELL

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

(2018) Antoine Italiano et al.   LANCET ONCOLOGY

Enhancer of zeste homolog 2 (EZH2) inhibitors

(2018) Nitya Gulati et al.   LEUKEMIA & LYMPHOMA

Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling

(2018) Pernilla Roswall et al.   NATURE MEDICINE

Caloric restriction inhibits mammary tumorigenesis in MMTV-ErbB2 transgenic mice through the suppression of ER and ErbB2 pathways and inhibition of epithelial cell stemness in premalignant mammary tissues

(2018) Zhikun Ma et al.   CARCINOGENESIS

Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance

(2017) Sheng Yu Ku et al.   SCIENCE

Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

(2016) Roisin M. Connolly et al.   CLINICAL CANCER RESEARCH

Role of RPL39 in Metaplastic Breast Cancer

(2016) Bhuvanesh Dave et al.   JNCI-Journal of the National Cancer Institute

Blocking c-Met–mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors

(2016) Yi Du et al.   NATURE MEDICINE

Targeting EZH2 in cancer

(2016) Kimberly H Kim et al.   NATURE MEDICINE

Enrichr: a comprehensive gene set enrichment analysis web server 2016 update

(2016) Maxim V. Kuleshov et al.   NUCLEIC ACIDS RESEARCH

A new transgenic mouse model for conditional overexpression of the Polycomb Group protein EZH2

(2016) Martijn A. J. Koppens et al.   TRANSGENIC RESEARCH

Role of RPL39 in Metaplastic Breast Cancer

(2016) Bhuvanesh Dave et al.   JNCI-Journal of the National Cancer Institute

IL-36γ Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses

(2015) Xuefeng Wang et al.   CANCER CELL

A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer

(2015) Zahi Mitri et al.   INVESTIGATIONAL NEW DRUGS

The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors

(2015) Daniel Zingg et al.   Nature Communications

Mammary Tumors Initiated by Constitutive Cdk2 Activation Contain an Invasive Basal-like Component

(2015) Patrick E. Corsino et al.   NEOPLASIA

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma

(2014) S. K. Kumar et al.   BLOOD

HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts

(2014) Patricia de Cremoux et al.   BREAST CANCER RESEARCH AND TREATMENT

Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario

(2014) M. Bonotto et al.   ONCOLOGIST

Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling

(2014) B. Dave et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition

(2013) Michael Amatangelo et al.   CELL CYCLE

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

(2013) John J Nemunaitis et al.   Journal of Translational Medicine

Invasive breast carcinomas in Ghana: high frequency of high grade, basal-like histology and high EZH2 expression

(2012) Judy Pang et al.   BREAST CANCER RESEARCH AND TREATMENT

Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer

(2012) Yaser R. Hussein et al.   HUMAN PATHOLOGY

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

NIPP1 maintains EZH2 phosphorylation and promoter occupancy at proliferation-related target genes

(2012) Nikki Minnebo et al.   NUCLEIC ACIDS RESEARCH

Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers

(2012) Marina De Brot et al.   PATHOLOGY

Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2

(2012) Sharad K. Verma et al.   ACS Medicinal Chemistry Letters

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

The analysis of 2 × 2 contingency tables-Yet again

(2011) John T. E. Richardson   STATISTICS IN MEDICINE

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA

(2010) S. Kaneko et al.   GENES & DEVELOPMENT

Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists

(2010) Sunil Badve et al.   MODERN PATHOLOGY

Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

(2010) David Parry et al.   MOLECULAR CANCER THERAPEUTICS

CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells

(2010) Yongkun Wei et al.   NATURE CELL BIOLOGY

Pathologic progression of mammary carcinomas in a C3(1)/SV40 T/t-antigen transgenic rat model of human triple-negative and Her2-positive breast cancer

(2010) M. J. Hoenerhoff et al.   TRANSGENIC RESEARCH

Targeted Overexpression of EZH2 in the Mammary Gland Disrupts Ductal Morphogenesis and Causes Epithelial Hyperplasia

(2009) Xin Li et al.   AMERICAN JOURNAL OF PATHOLOGY

Cdk2 suppresses cellular senescence induced by the c-myc oncogene

(2009) Stefano Campaner et al.   NATURE CELL BIOLOGY

Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation

(2009) P. Hydbring et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumour-immune cell interactions modulated by chemokines

(2008) Karin Jöhrer et al.   EXPERT OPINION ON BIOLOGICAL THERAPY